Revenue
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Coherus Oncology, Inc. (CHRS)
Price$1.42Cached quote
Net income
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Total cash / debt
CashTotal debt
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $42.2M | $26.4M | $257.2M | $211.0M | $326.6M | $475.8M | $356.1M | $0 | $1.6M | $189.5M | $30.0M | $31.1M | $2.8M | $1.9M |
| Gross profit | $28.4M | $17.7M | $98.3M | $141.0M | $269.0M | $438.2M | $339.0M | — | — | — | — | — | — | — |
| Gross margin | 67.24% | 66.93% | 38.19% | 66.79% | 82.36% | 92.08% | 95.20% | — | — | — | — | — | — | — |
| Research & development | $108.9M | $91.8M | $109.4M | $199.4M | $363.1M | $142.8M | $94.2M | $110.2M | $162.4M | $254.4M | $213.1M | $78.2M | $31.3M | $34.9M |
| Operating expenses | $223.3M | $226.0M | $460.4M | $467.9M | $590.4M | $319.5M | $248.3M | $204.4M | $233.7M | $306.0M | $249.1M | $95.8M | $38.7M | $40.4M |
| Operating income | −$181.1M | −$199.7M | −$203.2M | −$256.9M | −$263.9M | $156.3M | $107.8M | −$204.4M | −$232.1M | −$115.9M | −$219.1M | −$64.7M | −$36.0M | −$38.5M |
| Operating margin | −429.51% | −756.58% | −78.99% | −121.72% | −80.80% | 32.85% | 30.27% | — | −14,918.77% | −61.19% | −729.23% | −207.94% | −1,308.36% | −2,028.33% |
| EBITDA | −$179.8M | −$198.1M | −$200.0M | −$253.3M | −$260.4M | $159.2M | $111.0M | −$201.2M | −$228.7M | −$112.9M | −$217.2M | −$64.0M | −$35.6M | −$38.3M |
| EBITDA margin | −426.43% | −750.51% | −77.75% | −120.01% | −79.73% | 33.46% | 31.18% | — | −14,700.39% | −59.60% | −723.01% | −205.77% | −1,293.68% | −2,016.69% |
| Net income | $168.0M | $28.5M | −$237.9M | −$291.8M | −$287.1M | $132.2M | $89.8M | −$209.3M | −$238.2M | −$127.3M | −$223.3M | −$87.1M | −$53.6M | −$33.0M |
| Net profit margin | 398.43% | 108.03% | −92.48% | −138.24% | −87.92% | 27.79% | 25.23% | — | −15,306.56% | −67.20% | −743.18% | −280.12% | −1,949.65% | −1,738.70% |
| Basic EPSper basic share | $1.43 | $0.25 | -$2.53 | -$3.76 | -$3.81 | $1.85 | $1.29 | -$3.22 | -$4.48 | -$3.04 | -$6.01 | -$10.64 | -$16.10 | -$15.85 |
| Diluted EPSper diluted share | $1.43 | $0.25 | -$2.53 | -$3.76 | -$3.81 | $1.62 | $1.23 | -$3.22 | -$4.48 | -$3.04 | -$6.01 | -$10.64 | -$16.10 | -$15.85 |
Owners
Reported shareholders
8.45%of listed shares
Timothy G. Youngquist 2020 Irrevocable Trust13.05M shares · Jun 30, 2026
View holders
| Holder | % owned |
|---|---|
Timothy G. Youngquist 2020 Irrevocable Trust | 8.45%13.05M shares |
BlackRock, Inc. | 7.77%12M shares |
VANGUARD CAPITAL MANAGEMENT LLC | 3.85%5.95M shares |
GEODE CAPITAL MANAGEMENT, LLC | 2.39%3.69M shares |
SAMSARA BIOCAPITAL, LLC | 2.22%3.43M shares |
Kohlberg Kravis Roberts & Co. L.P. | 1.97%3.04M shares |
STATE STREET CORP | 1.54%2.38M shares |
TWO SIGMA INVESTMENTS, LP | 1.46%2.26M shares |
CM Management, LLC | 1.36%2.1M shares |
C WorldWide Group Holding A/S | 1.25%1.93M shares |
Alyeska Investment Group, L.P. | 1.12%1.73M shares |
Hudson Bay Capital Management LP | 1.10%1.69M shares |
Lanfear Dennis M | ≈1.02%1.57M shares |
AQR CAPITAL MANAGEMENT LLC | 0.86%1.33M shares |
CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.80%1.23M shares |
PANAGORA ASSET MANAGEMENT INC | 0.74%1.14M shares |
NORTHERN TRUST CORP | 0.73%1.13M shares |
VANGUARD FIDUCIARY TRUST CO | 0.66%1.02M shares |
NOMURA ASSET MANAGEMENT INTERNATIONAL INC. | 0.58%900K shares |
VANGUARD PORTFOLIO MANAGEMENT LLC | 0.57%883.45K shares |
Percentages use 154.47M shares of this listed class outstanding on Jun 30, 2026. ≈ compares the latest reported holding with a share total from a different date; it is not a confirmed current stake.
Gray completes the 100% scale. Reported positions may overlap; holders have different reporting dates.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| May 23, 2025Form 4 | Wahlstrom MatsDirector | SellCommon Stock · indirect | 100.0K | $0.74 | $74.0K | 0 |